CCHT(000661)2025-05-28 10:26Group 1: Company Strategy and Development - The company aims to establish a globally influential biopharmaceutical group, focusing on innovation in the health sector and internationalization as a guiding strategy [2] - The company will enhance innovation investment and cooperation to cultivate new economic growth points, while also improving brand value and operational efficiency [2][3] - The company emphasizes a principle of "optimizing existing resources, enhancing new growth, and strengthening research and development" [2] Group 2: Product Development and Market Position - The company has approved 12 indications for its growth hormone products, maintaining a leading market share in China [4][5] - The long-acting growth hormone has undergone extensive clinical trials, demonstrating safety and efficacy with over 10,000 real-world applications [4] - The company is actively promoting its growth hormone products through educational initiatives to enhance understanding among healthcare professionals and patients [5] Group 3: Financial Performance and Investor Relations - As of April 30, 2025, the company has repurchased 3,894,517 shares, accounting for 0.95% of its total share capital, with a total transaction amount of approximately RMB 399.99 million [15] - The company is committed to optimizing resource allocation while controlling costs to ensure a balance between research investment and output efficiency [13][14] - The company will continue to enhance transparency in investor relations through various communication channels [15] Group 4: Research and Development - The company is focused on high-quality development through innovation, with plans to explore cutting-edge technologies and establish an intelligent research platform [10][14] - The company is preparing for European market applications for several products, including short-acting growth hormone and other innovative drugs [8] Group 5: Real Estate and Asset Management - The company is actively managing its real estate segment, focusing on inventory reduction and transitioning to a light asset operation model [11][12] - The real estate division is involved in urban renewal projects, integrating with the pharmaceutical sector to enhance resource utilization [11]